Shots:

• Samsung Biologics entered into an agreement with APRINOIA Therapeutics to develop an anti-tau mAb for treating primary and secondary tauopathies- including PSP and AD
• APRINOIA will utilize its Ab platform for selecting the candidate and targets specific pathological tau aggregates with novel conformation-dependent epitopes with an aim to slow down disease progression
• The collaboration encompasses product's development phase from cell line development- process development- cGMP manufacturing to IND filing while with the collaboration Samsung Biologics has reconfirmed its position as a global leading CMO- CDO- and CRO partner

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Samsung Biologics